AX-2025-019288
CJC-1295 with DAC · 5 mg declared · AmbioPharm, Inc. · lot AMB-2412-N5535
- Report ID
- AX-2025-019288
- Compound
- CJC-1295 with DAC
- Compound class
- Growth-hormone axis peptides
- Supplier
- AMB — AmbioPharm, Inc.
- Batch / lot
- AMB-2412-N5535
- Declared label claim
- 5mg
- Laboratory
- Janoshik Analytical
- Assay date
- 12 Jan 2025
- Submitted
- 25 Jan 2025
- Quarter
- 2025-Q1
- Submitter
- d.aalto
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 30 min gradient, 214 nm | 99.17 | % area | ≥ 97.5 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.83 | % area | ≤ 2.5 | PASS |
| Largest single impurity | RP-HPLC — mod-GRF (1-29) (−279 Da) | 0.34 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 3644.9748 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 3644.8669 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | -29.6 | ppm | ± 15 | FAIL |
| Total peptide content | by difference from the gravimetric mass balance | 89.91 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 89.16 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 5.63 | mg | 5 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 5.020 | mg | 5 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 100.4 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 4.50 | % | ≤ 9.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 5.35 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.24 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White to pale-yellow cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 6.00 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 30 min gradient | 14.48 | min | 14.62 ± 0.35 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.30 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 57,641 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs deamidated (+1 Da) | 1.05 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | CJC-1295 with DAC — main peak | 14.48 | 4,819,969 | 99.17 | — |
| 2 | mod-GRF (1-29) (−279 Da) | 12.72 | 16,525 | 0.34 | -279.235 |
| 3 | hydrolysed maleimide (+18 Da) | 13.86 | 10,207 | 0.21 | +18.011 |
| 4 | maleimide dimer | 16.90 | 7,290 | 0.15 | +3644.975 |
| 5 | deamidated (+1 Da) | 14.22 | 6,318 | 0.13 | +0.984 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 3644.9748 Da, computed from C165H269N47O46. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 5+ | 730.0022 | 729.9807 | -0.0215 | 9.2 |
| 4+ | 912.2510 | 912.2240 | -0.0270 | 56.9 |
| 3+ | 1215.9989 | 1215.9629 | -0.0360 | 100.0 |
| 2+ | 1823.4947 | 1823.4407 | -0.0540 | 55.0 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 4.50 |
| Counter-ion (acetate) | ion chromatography | 5.35 |
| Residual solvent + inorganic residue | estimated | 0.24 |
| Total peptide content | by difference | 89.91 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 98.99 | 99.17 | divergence -0.18 pp vs batch median |
| Total impurities (% area) | 1.01 | 0.83 | |
| Largest single impurity (% area) | 0.69 | 0.34 | |
| Water (%) | 3.8 | 4.50 | |
| Counter-ion (%) | 5.3 | 5.35 | |
| Peptide content (%w/w) | 90.3 | 89.91 | |
| Endotoxin (EU/mg) | 1.16 | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (ambient, 18 d) → laboratory (hand-carried, 9 d) → assay.
- Assay date
- 12 Jan 2025
- Submitted to the index
- 25 Jan 2025
- Laboratory
- Janoshik Analytical, Ostrava, Czechia
- Method basis
- 30 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations 3
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Related records
Same batch — lot AMB-2412-N5535 n=1
This is the only report on this lot. One report is not a batch characterisation.
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041681 | TFS | TFS-{CAT}-9675 | PeptideMeter | 2026-Q3 | 98.82 | 3.67 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041867 | SinoPep | SNP-2607-C3886 | Janoshik | 2026-Q3 | 99.24 | 5.12 | — | Laboratory-retained | 1 | FAIL |
| AX-2026-041682 | TFS | TFS-{CAT}-9675 | Nordanalyt | 2026-Q3 | 98.94 | 3.24 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041683 | TFS | TFS-{CAT}-9675 | Medutest | 2026-Q3 | 98.68 | 3.46 | 97.0 | Buyer-sourced | 0 | PASS |
| AX-2026-043471 | BCH | BCH-2607-H5235 | Janoshik | 2026-Q3 | 97.46 | 5.48 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-043477 | BCH | BCH-2607-H5235 | VendorInvestigate | 2026-Q3 | 97.62 | 5.32 | 99.6 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-043470 | BCH | BCH-2607-H5235 | Janoshik | 2026-Q3 | 97.76 | 6.11 | 99.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043478 | BCH | BCH-2607-H5235 | PeptideMeter | 2026-Q3 | 97.63 | 5.42 | 90.1 | Buyer-sourced | 1 | MARGINAL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042002 | Semaglutide | AMB-2607-N6274 | VendorInvestigate | 2026-Q3 | 98.23 | 6.37 | 97.1 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042012 | GHRP-6 | AMB-2603-S5667 | Janoshik | 2026-Q3 | 99.37 | 5.90 | 88.8 | Laboratory-retained | 1 | MARGINAL |
| AX-2026-041974 | Tirzepatide | AMB-2603-C5112 | Nordanalyt | 2026-Q3 | 98.20 | 3.41 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041975 | Tirzepatide | AMB-2603-C5112 | Medutest | 2026-Q3 | 97.88 | 3.45 | 106.9 | Laboratory-retained | 0 | PASS |
| AX-2026-042005 | Semaglutide | AMB-2607-N6274 | PeptideMeter | 2026-Q3 | 98.09 | 6.48 | 98.6 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042008 | Epitalon | AMB-2602-Y6433 | Janoshik | 2026-Q3 | 99.30 | 8.75 | 105.1 | Buyer-sourced | 0 | PASS |
| AX-2026-042021 | TB-500 | AMB-2602-P5987 | VendorInvestigate | 2026-Q3 | 99.86 | 4.79 | 101.4 | Buyer-sourced | 0 | PASS |
| AX-2026-042015 | GHRP-6 | AMB-2603-S5667 | Janoshik | 2026-Q3 | 99.54 | 6.44 | 97.1 | Buyer-sourced | 0 | PASS |